McGuire Investment Group LLC Cuts Position in IQVIA Holdings Inc. $IQV

McGuire Investment Group LLC cut its stake in IQVIA Holdings Inc. (NYSE:IQV) by 0.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,637 shares of the medical research company’s stock after selling 255 shares during the quarter. McGuire Investment Group LLC’s holdings in IQVIA were worth $8,295,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in IQV. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 131 shares during the period. Golden State Wealth Management LLC boosted its position in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after purchasing an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA in the 1st quarter worth $33,000. ST Germain D J Co. Inc. boosted its position in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares in the last quarter. Finally, Larson Financial Group LLC boosted its position in shares of IQVIA by 109.9% in the 1st quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock worth $48,000 after purchasing an additional 144 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Up 7.4%

NYSE:IQV opened at $203.94 on Thursday. The firm has a market capitalization of $34.67 billion, a P/E ratio of 29.51, a PEG ratio of 2.08 and a beta of 1.32. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $237.34. The company’s fifty day moving average price is $187.68 and its 200-day moving average price is $167.43. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Activity

In other news, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company’s stock, valued at $557,352.30. The trade was a 15.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on IQV shares. Barclays raised their price objective on IQVIA from $165.00 to $185.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 23rd. Cowen reissued a “buy” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Truist Financial raised their price objective on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, UBS Group lifted their price target on IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Eighteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $229.64.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.